- Current Clinical Practice in Cytoreductive Surgery for Advanced Ovarian Cancer A European Survey2011 | First Faculty of Medicine
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerPublication without faculty affiliation
- Controversies in the modern treatment of advanced ovarian cancer2001 | Faculty of Medicine in Hradec Králové
- European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery2016 | First Faculty of Medicine
- Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review2023 | First Faculty of Medicine
- Guideline for treatment of advanced ovarian cancer in the department of radiotherapy and oncology Charles University Hospital Plzeň, Czech Republic1999 | Faculty of Medicine in Pilsen
- Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer2020 | First Faculty of Medicine
- AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial2023 | First Faculty of Medicine
- Importance of a multidisciplinary approach to the treatment of ovarian cancer and its effect on prolonging overall survival - case reports2020 | Third Faculty of Medicine
- PARP inhibitor olaparib great benefit for a defined group of patients with BRCA positive ovarian cancer2019 | Faculty of Medicine in Pilsen
- Olaparib as a maintenance therapy in newly diagnosed patients with ovarian cancer - SOLO1 study results2022 | Third Faculty of Medicine
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms2019 | First Faculty of Medicine
- Nutritional support/status in gynaecological cancer2016 | Faculty of Medicine in Pilsen
- An important progress in the treatment of ovarian cancer after 20 years2012 | Faculty of Medicine in Pilsen
- European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerPublication without faculty affiliation
- New trends in systemic treatment of ovarian cancer2018 | Faculty of Medicine in Pilsen
- Ovarian cancer stem cells2012 | Faculty of Medicine in Pilsen
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)2022 | Third Faculty of Medicine
